SG143042A1 - Treatment for diabetes - Google Patents

Treatment for diabetes

Info

Publication number
SG143042A1
SG143042A1 SG200402994-8A SG2004029948A SG143042A1 SG 143042 A1 SG143042 A1 SG 143042A1 SG 2004029948 A SG2004029948 A SG 2004029948A SG 143042 A1 SG143042 A1 SG 143042A1
Authority
SG
Singapore
Prior art keywords
treatment
diabetes
kit
ingredient
patient
Prior art date
Application number
SG200402994-8A
Other languages
English (en)
Inventor
Indu Parikh
Anne Lane
Ronald V Nardi
Stephen J Brand
Original Assignee
Gen Hospital Corp
Waratah Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp, Waratah Pharmaceuticals Inc filed Critical Gen Hospital Corp
Publication of SG143042A1 publication Critical patent/SG143042A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2207—Gastrins; Cholecystokinins [CCK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/595—Gastrins; Cholecystokinins [CCK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
SG200402994-8A 1999-01-29 1999-10-27 Treatment for diabetes SG143042A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/241,100 US6558952B1 (en) 1992-12-14 1999-01-29 Treatment for diabetes

Publications (1)

Publication Number Publication Date
SG143042A1 true SG143042A1 (en) 2008-06-27

Family

ID=22909247

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200402994-8A SG143042A1 (en) 1999-01-29 1999-10-27 Treatment for diabetes

Country Status (11)

Country Link
US (4) US6558952B1 (fr)
EP (1) EP1071447A1 (fr)
JP (2) JP2004506591A (fr)
KR (2) KR20050096212A (fr)
CN (2) CN101524530A (fr)
AU (2) AU774746B2 (fr)
CA (1) CA2326741A1 (fr)
IL (1) IL138784A0 (fr)
SE (1) SE0003508L (fr)
SG (1) SG143042A1 (fr)
WO (1) WO2000044400A1 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6558952B1 (en) * 1992-12-14 2003-05-06 Waratah Pharmaceuticals, Inc. Treatment for diabetes
GB9409496D0 (en) * 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
US20040037818A1 (en) * 1998-07-30 2004-02-26 Brand Stephen J. Treatment for diabetes
US20020099008A1 (en) 1999-04-26 2002-07-25 Daniel R. Twardzik Method for stimulating hematopoiesis using tgf-alpha
WO2000065028A2 (fr) 1999-04-26 2000-11-02 Stem Cell Pharmaceuticals, Inc. Polypeptides tgf-α, fragments fonctionnels et leurs procedes d'utilisation
US6815418B2 (en) 1999-08-19 2004-11-09 Kaleidos Pharma, Inc. TGF-α polypeptides, functional fragments and methods of use therefor
US6677307B2 (en) 1999-08-19 2004-01-13 Kaleidos Pharma, Inc. TGF-α polypeptides, functional fragments and methods of use therefor
US20020193301A1 (en) 1999-08-19 2002-12-19 Stem Cell Pharmaceuticals, Inc. TGF-alpha polypeptides, functional fragments and methods of use therefor
JP2003522131A (ja) * 1999-08-19 2003-07-22 ステム セル ファーマシューティカルズ，インコーポレーテッド ＴＧＦ−αポリペプチド、機能性断片およびそれらの利用法
US6992060B2 (en) * 2001-01-12 2006-01-31 Waratah Pharmaceuticals, Inc. Prolonged efficacy of islet neogenesis therapy methods with a gastrin/CCK receptor ligand and an EGF receptor ligand composition in subjects with preexisting diabetes
US7037504B2 (en) * 2001-10-23 2006-05-02 Waratah Pharmaceuticals, Inc. Epidermal growth factor protein and gene, and methods of use therefor
US20040005301A1 (en) * 2002-02-12 2004-01-08 Goldman Steven A. Identification and high-yield isolation of human pancreatic islet progenitor and stem cells
AU2003231864A1 (en) * 2002-05-24 2003-12-12 University Of Alberta Treatment for diabetes
EP1837031B1 (fr) * 2002-06-07 2009-10-14 Waratah Pharmaceuticals, Inc. Methodes et compositions pour le traitement du diabete
ATE445407T1 (de) * 2002-06-07 2009-10-15 Waratah Pharmaceuticals Inc Methoden und kompositionen um diabetes zu behandeln
JP2006506386A (ja) * 2002-10-22 2006-02-23 ワラタ ファーマシューティカルズ， インコーポレイテッド 糖尿病の処置
US20040229810A1 (en) * 2002-10-22 2004-11-18 Antonio Cruz Gastrin compositions and formulations, and methods of use and preparation
US7025791B2 (en) 2002-12-02 2006-04-11 Gi Dynamics, Inc. Bariatric sleeve
AU2004233911A1 (en) * 2003-04-30 2004-11-11 Waratah Pharmaceuticals, Inc. Combined use of keratinocyte growth factor agonists and gastrin compounds
JP2007513059A (ja) * 2003-05-27 2007-05-24 ワラタ ファーマシューティカルズ， インコーポレイテッド ガストリン化合物を含む組成物および糖尿病におけるそれらの使用
WO2004106921A2 (fr) * 2003-05-27 2004-12-09 Mcgill University Plate-forme in vitro de criblage d'agents inducteurs de la neogenese des ilots de langerhans
US20080039379A1 (en) * 2003-05-27 2008-02-14 Waratah Pharmaceuticals, Inc. Compositions Comprising Gastrin Compounds and Their Use in Diabetes
RU2006131046A (ru) * 2004-01-30 2008-03-10 Уэрейта Фармасьютикалз, Инк. (Ca) Совместное применение агониста glp-1 и соединений гастрина
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
CA2571957A1 (fr) * 2004-07-01 2006-01-12 Waratah Pharmaceuticals, Inc. Utilisation combinee d'agoniste cd3 et de gastrine pour le traitement du diabete
WO2007022123A2 (fr) * 2005-08-11 2007-02-22 Amylin Pharmaceuticals, Inc. Polypeptides hybrides presentant des proprietes selectionnables
US20100144613A1 (en) * 2005-10-07 2010-06-10 Antonio Cruz Combined use of DPP-IV Inhibitors and Gastrin Compounds
US8093038B2 (en) * 2007-09-17 2012-01-10 Illinois Institute Of Technology Apparatus and method for encapsulating pancreatic cells
WO2010002492A1 (fr) * 2008-04-29 2010-01-07 University Of Chicago Procédés d’utilisation de dérivés d’adénine pour le traitement du diabète et d’autres troubles
JP5838557B2 (ja) 2010-07-05 2016-01-06 ソニー株式会社 生体情報処理方法および装置、並びに記録媒体

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464363A (en) * 1979-12-20 1984-08-07 Merck & Co., Inc. Ajuvants for rectal delivery of drug substances
EP0239716B1 (fr) * 1986-01-10 1993-03-31 Alfio Bertolini Compositions pharmaceutiques contenant des peptides du groupe du cholecystokinine-céruléine pour le traitement des insuffisances respiratoires et cardiocirculatoires
WO1995019785A1 (fr) * 1994-01-24 1995-07-27 Research Triangle Pharmaceuticals Ltd. Traitement du diabete juvenile
WO1996011701A1 (fr) * 1994-10-14 1996-04-25 Glaxo Wellcome Inc. Compositions gastro-resistantes a base de derives de benzodiazepine-1,5 presentant une activite cck antagoniste ou agoniste
WO1997025030A1 (fr) * 1996-01-08 1997-07-17 Astra Aktiebolag Formes galeniques effervescentes a unites multiples comprenant un inhibiteur de la pompe a protons

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE38892B1 (en) * 1973-03-28 1978-06-21 Ici Ltd Pharmaceutical compositions
JPS6028994A (ja) * 1983-07-08 1985-02-14 Wakunaga Seiyaku Kk 〔２１―ロイシン〕ヒトウロガストロン
US4686283A (en) * 1985-04-16 1987-08-11 Syntex (U.S.A.) Inc. Analogs of transforming and epidermal growth factor fragments for therapy and diagnosis
EP0284898A3 (fr) * 1987-04-02 1990-06-27 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Hinge peptide, son procédé de préparation et son emploi pour la préparation d'immunogènes synthétiques
US5102789A (en) * 1989-03-15 1992-04-07 The Salk Institute Biotechnology/Industrial Associates, Inc. Production of epideramal growth factor in pichia pastoris yeast cells
US5023077A (en) * 1989-01-24 1991-06-11 Aphton Corporation Immunogenic compositions and methods for the treatment and prevention of gastric and duodenal ulcer disease
US4997950A (en) * 1989-04-20 1991-03-05 Richard Finbar Murphy Novel C-terminal gastrin antagonists
US5158935A (en) * 1989-05-12 1992-10-27 Chiron Corporation Human epidermal growth factor having substitution at position 11
IE68593B1 (en) * 1989-12-06 1996-06-26 Sanofi Sa Heterocyclic substituted acylaminothiazoles their preparation and pharmaceutical compositions containing them
WO1992002246A1 (fr) * 1990-08-02 1992-02-20 Indu Parikh Compositions de facteur de croissance, preparation et emploi
US5434135A (en) * 1990-08-02 1995-07-18 Indu Parikh Growth factor compositions, preparation and use
US5187154A (en) * 1990-12-13 1993-02-16 Board Of Regents, The University Of Texas System Diagnosis and treatment of humans with diabetes or at risk to develop diabetes
US5468727A (en) * 1990-12-13 1995-11-21 Board Of Regents, The University Of Texas System Methods of normalizing metabolic parameters in diabetics
EP0586549B1 (fr) * 1991-05-10 2000-09-20 Genentech, Inc. Selectionner des agonistes et des antagonistes de ligands
DK36392D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
US5290920A (en) * 1992-04-16 1994-03-01 Allelix Biopharmaceuticals Inc. Method of purifying human epidermal growth factor
US6558952B1 (en) * 1992-12-14 2003-05-06 Waratah Pharmaceuticals, Inc. Treatment for diabetes
US5885956A (en) * 1992-12-14 1999-03-23 Research Triangle Pharmaceuticals Treatment for diabetes using a gastrin/CCK receptor ligand and an EGF receptor ligand
US6284727B1 (en) * 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
US5624895A (en) * 1994-02-18 1997-04-29 Georgetown University Medical Center Treatment and/or prevention of type I diabetes mellitus with gamma interferon administration
WO1995029690A1 (fr) * 1994-04-29 1995-11-09 The Trustees Of The University Of Pennsylvania Peptides biologiquement actifs et procedes permettant leur identification
US5587309A (en) * 1994-04-29 1996-12-24 The United States Of America As Represented By The Department Of Health And Human Services Method of stimulating proliferation and differentiation of human fetal pancreatic cells ex vivo
GB9409496D0 (en) * 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
US5993850A (en) * 1994-09-13 1999-11-30 Skyepharma Inc. Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances
US6346390B1 (en) * 1996-03-08 2002-02-12 Receptron, Inc. Receptor derived peptides involved in modulation of response to ligand binding
JP2001521897A (ja) * 1997-10-31 2001-11-13 スミスクライン・ビーチャム・コーポレイション 新規な金属錯体
JP2001525371A (ja) * 1997-12-05 2001-12-11 イーライ・リリー・アンド・カンパニー Ｇｌｐ−１製剤
US20040037818A1 (en) * 1998-07-30 2004-02-26 Brand Stephen J. Treatment for diabetes
EP1306091A3 (fr) * 1998-07-31 2003-05-21 Novo Nordisk A/S Stimulation de la prolifération des cellules de beta
US6242666B1 (en) * 1998-12-16 2001-06-05 The Scripps Research Institute Animal model for identifying a common stem/progenitor to liver cells and pancreatic cells
US6326201B1 (en) * 1999-02-10 2001-12-04 Curis, Inc. Pancreatic progenitor cells, methods and uses related thereto
US6815203B1 (en) * 1999-06-23 2004-11-09 Joslin Diabetes Center, Inc. Methods of making pancreatic islet cells
WO2001039784A1 (fr) * 1999-12-06 2001-06-07 The General Hospital Corporation Cellules souches pancreatiques et leur utilisation en transplantation
AU2001233502B2 (en) * 2000-02-18 2006-02-02 The Walter And Eliza Hall Institute Of Medical Research Pancreatic islet cell growth factors
US6992060B2 (en) * 2001-01-12 2006-01-31 Waratah Pharmaceuticals, Inc. Prolonged efficacy of islet neogenesis therapy methods with a gastrin/CCK receptor ligand and an EGF receptor ligand composition in subjects with preexisting diabetes
CA2442177A1 (fr) * 2001-03-29 2002-10-10 Ixion Biotechnology, Inc. Procede de transdifferentiation de cellules souches non pancreatiques dans la voie de differentiation du pancreas
WO2002096203A1 (fr) * 2001-05-25 2002-12-05 Cythera, Inc. Differentiation de cellules souches
EP1412384B1 (fr) * 2001-06-28 2007-12-26 Novo Nordisk A/S Formulation stable de glp-1 modifie
US20030049236A1 (en) * 2001-07-27 2003-03-13 Arhus Amt Immortalized stem cells
US7037504B2 (en) * 2001-10-23 2006-05-02 Waratah Pharmaceuticals, Inc. Epidermal growth factor protein and gene, and methods of use therefor
EP2264146A1 (fr) * 2001-12-07 2010-12-22 Geron Corporation Cellules d'îlots de Langerhans à partir de cellules souches embryonnaires humaines
AU2003231864A1 (en) * 2002-05-24 2003-12-12 University Of Alberta Treatment for diabetes
ATE445407T1 (de) * 2002-06-07 2009-10-15 Waratah Pharmaceuticals Inc Methoden und kompositionen um diabetes zu behandeln
EP1837031B1 (fr) * 2002-06-07 2009-10-14 Waratah Pharmaceuticals, Inc. Methodes et compositions pour le traitement du diabete
US20040229810A1 (en) * 2002-10-22 2004-11-18 Antonio Cruz Gastrin compositions and formulations, and methods of use and preparation
JP2006506386A (ja) * 2002-10-22 2006-02-23 ワラタ ファーマシューティカルズ， インコーポレイテッド 糖尿病の処置

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464363A (en) * 1979-12-20 1984-08-07 Merck & Co., Inc. Ajuvants for rectal delivery of drug substances
EP0239716B1 (fr) * 1986-01-10 1993-03-31 Alfio Bertolini Compositions pharmaceutiques contenant des peptides du groupe du cholecystokinine-céruléine pour le traitement des insuffisances respiratoires et cardiocirculatoires
WO1995019785A1 (fr) * 1994-01-24 1995-07-27 Research Triangle Pharmaceuticals Ltd. Traitement du diabete juvenile
WO1996011701A1 (fr) * 1994-10-14 1996-04-25 Glaxo Wellcome Inc. Compositions gastro-resistantes a base de derives de benzodiazepine-1,5 presentant une activite cck antagoniste ou agoniste
WO1997025030A1 (fr) * 1996-01-08 1997-07-17 Astra Aktiebolag Formes galeniques effervescentes a unites multiples comprenant un inhibiteur de la pompe a protons

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FUNCTION AND REGULATION OF GASTRIN IN TRANSGENIC MICE: A REVIEW *
PANCREATIC GASTRIN STIMULATES ISLET DIFFERENTIATION OF TRANSFORM *

Also Published As

Publication number Publication date
IL138784A0 (en) 2001-10-31
KR20010074466A (ko) 2001-08-04
SE0003508D0 (sv) 2000-09-29
AU2004218687A1 (en) 2004-11-04
CA2326741A1 (fr) 2000-08-03
CN100482686C (zh) 2009-04-29
AU2004218687B2 (en) 2008-02-21
US6558952B1 (en) 2003-05-06
US20090041731A1 (en) 2009-02-12
US20040209816A1 (en) 2004-10-21
AU774746B2 (en) 2004-07-08
KR20050096212A (ko) 2005-10-05
JP2008094854A (ja) 2008-04-24
US20020081285A1 (en) 2002-06-27
CN101524530A (zh) 2009-09-09
JP2004506591A (ja) 2004-03-04
EP1071447A1 (fr) 2001-01-31
WO2000044400A1 (fr) 2000-08-03
CN1308544A (zh) 2001-08-15
SE0003508L (sv) 2000-11-21
AU1331900A (en) 2000-08-18

Similar Documents

Publication Publication Date Title
SG143042A1 (en) Treatment for diabetes
HUP0200556A2 (en) Medicament for treating diabetes
HK1031201A1 (en) Mixing/charging port for medical treatment.
HK1048427A1 (en) Drug delivery device.
HK1048428A1 (en) Ophthalmic drug delivery device.
IL151202A0 (en) Phenyl derivatives, a process for their praparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy
HUP0002628A2 (en) Pharmaceutical combinations for treating diabetes
EP1194173A4 (fr) Administration de medicament guidee par rayon x
ZA962536B (en) Pharmaceutical composition for transdermal administration.
HK1044723A1 (en) Mixing/charging port for medical treatment.
ZA975866B (en) Novel heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases.
MY125978A (en) Admantane derivatives
SI1242055T1 (sl) S hidrogelom prenašana odmerna oblika zdravila
IL161682A0 (en) A medicament container, a medicament dispensing kit for administering medication and a method for packaging the same
HK1040679A1 (zh) 裝兩種分開的、不穩定物質的藥物容器
HK1033278A1 (en) Pharmaceutical preparation for use in anti-asthma therapy.
HK1009814A1 (en) Five-membered heterocycles having biphenylsulfonylsubstitution, process for their prparation, their use as a medicament or diagnostic, and medicament .
GB9709486D0 (en) Blending medical composition with sustained medicament releasability and process for preparing the same
ZA972147B (en) Dimethyl-(3-aryl-but-3-enyl)-amine compounds as pharmaceutical active ingredients.
HUP0201047A2 (en) Steroid compounds with a c17-alkyl side chain and an aromatic a-ring, process for their preparation and pharmaceutical compositions containing the compounds
ZA97976B (en) Uniform drug delivery theraphy.
HUP0301333A2 (hu) Gyógyszer szuperdezintegráns, eljárás az előállítására és alkalmazása
PL340948A1 (en) Syringe, in particular that for taking blood samples from patients
HUP0103852A3 (en) Container for intravenous administration
EP1049424A4 (fr) Forme posologique de medicament reposant sur le gradient de teorell-meyer